pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Beyfortus
drug
save

nirsevimab

Marketedupdated 6mo ago
by Sanofi-Aventis US LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • drugBEYFORTUS20 co-mentions · 5 sources
  • tagApproval20 co-mentions · 5 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

all catalysts(5)

approval · 5
Jul 17, 2023
approval
$AZN178.76-1.93%
3y ago
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Feb 23, 2024
approval
$AZN178.76-1.93%
3y ago
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Aug 22, 2024
approval
$AZN178.76-1.93%
2y ago
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Oct 20, 2025
approval
$AZN178.76-1.93%
1y ago
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Apr 7, 2026
approval
$AZN178.76-1.93%
8mo ago
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→

Trials studying nirsevimab

  • —A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korearecruitingn=3,000
  • —An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechiacompletedn=257
  • —RSV Immunisation Status in Queensland (Australia)not yet recruitingn=1,200
  • phase3A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimabcompletedn=33
  • phase3Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in Chinacompletedn=800
  • phase4Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in Indiaactive not recruitingn=110
  • phase2Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infantsnot yet recruitingn=36
  • EP1A Clinical Trial of SIBP-A16 Injection in Healthy Adultsrecruitingn=140

News(1)

  • Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
    Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported thi…
    biospace · 19d ago
brand
Beyfortus
generic
nirsevimab-alip
MOA
12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .
indication
Respiratory Syncytial Virus (RSV) Infections
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?